The Latest Analyst Ratings for Bio-Rad Laboratories

Within the last quarter, Bio-Rad Laboratories (NYSE:BIO) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

Within the last quarter, Bio-Rad Laboratories (NYSE:BIO) has observed the following analyst ratings:

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 1 3 0 0 0
Last 30D 0 1 0 0 0
1M Ago 0 0 0 0 0
2M Ago 1 2 0 0 0
3M Ago 0 0 0 0 0

These 4 analysts have an average price target of $546.5 versus the current price of Bio-Rad Laboratories at $376.035, implying upside.

Below is a summary of how these 4 analysts rated Bio-Rad Laboratories over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

price target chart

This current average represents a 9.52% decrease from the previous average price target of $604.00.

Stay up to date on Bio-Rad Laboratories analyst ratings.

How Are Analyst Ratings Determined?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

General Motors’ Potential In EV Transformation Weighed By Analysts After Q1 Beat- Was This a ‘Prove Me’ Quarter For CEO Mary Barra?

General Motors shares are trading higher on Tuesday after raising its outlook for FY24, following a first-quarter beat. According to Wedbush analyst Daniel Ives, the company is focusing heavily on profitability, with expenses continuing to be a big priority. BofA Securities analyst John Murphy said in a new investor note that there was optimism heading into the quarter.

GM